IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER

被引:275
作者
ALBERTS, DS
GREEN, S
HANNIGAN, EV
OTOOLE, R
STOCKNOVACK, D
ANDERSON, P
SURWIT, EA
MALVLYA, VK
NAHHAS, WA
JOLLES, CJ
机构
[1] SW ONCOL GRP, CTR STAT, SEATTLE, WA USA
[2] UNIV ARIZONA, CTR CANC, TUCSON, AZ 85721 USA
[3] UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA
[4] DAYTON COMMUNITY CLIN ONCOL PROGRAM, DAYTON, OH USA
[5] UNIV UTAH, MED CTR, SALT LAKE CITY, UT 84112 USA
[6] OHIO STATE UNIV, MED CTR, COLUMBUS, OH 43210 USA
[7] WAYNE STATE UNIV, MED CTR, DETROIT, MI 48202 USA
关键词
D O I
10.1200/JCO.1992.10.5.706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide as primary chemotherapy for stage III (suboptimal) and stage IV ovarian cancer. Patients and Methods: Three hundred forty-two patients were randomly assigned to treatment with six courses of intravenous (IV) cisplatin 100 mg/m2 plus IV cyclophosphamide 600 mg/m2, or IV carboplatin 300 mg/m2 plus IVcyclophosphamide 600 mg/m2. Results: The estimated median survivals were 17.4 and 20.0 months for the cisplatin and carboplatin study arms, respectively. The null hypothesis of a 30% survival superiority with the cisplatin arm was refected at the P = .02 level. Clinical response rates were 52% for the cispla-tin arm and 61% for the carboplatin arm. Pathologic complete response rates were similar for both study arms. There was less thrombocytopenia on the cisplatin arm (P < .001); however, there was less nausea and emesis (P < .001 for courses 1 to 5), renal toxicity (P < .001), anemia (P = .01), hearing loss (P < .001), tinnitus (P = .01 ), neuromuscular toxicfties (P = .001), and alopecia (P < .001) on the carboplatin arm. Conclusion: Carboplatin-cyclophosphamide proved to have a significantly better therapeutic index than cisplafin-cyclophosphamide in patients with stage III (suboptimal) and stage IV ovarian cancer. © 1992 by American Society of Clinical Oncology.
引用
收藏
页码:706 / 717
页数:12
相关论文
共 45 条
  • [31] MARSONI S, 1987, LANCET, V2, P353
  • [32] MCKENZIE RS, 1991, P AN M AM SOC CLIN, V10, P186
  • [33] NICHOLS C, 1988, P AN M AM SOC CLIN, V7, P118
  • [34] HIGH-DOSE CARBOPLATIN IN REFRACTORY OVARIAN-CANCER PATIENTS
    OZOLS, RF
    OSTCHEGA, Y
    CURT, G
    YOUNG, RC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (02) : 197 - 201
  • [35] OZOLS RF, 1985, SEMIN ONCOL, V12, P21
  • [36] PIEL IJ, 1974, CANCER CHEMOTH REP 1, V58, P871
  • [37] SEQUENTIAL TREATMENT ASSIGNMENT WITH BALANCING FOR PROGNOSTIC FACTORS IN CONTROLLED CLINICAL TRIAL
    POCOCK, SJ
    SIMON, R
    [J]. BIOMETRICS, 1975, 31 (01) : 103 - 115
  • [38] CISPLATIN-CYCLOPHOSPHAMIDE VERSUS CARBOPLATIN-CYCLOPHOSPHAMIDE IN ADVANCED OVARIAN-CANCER - A RANDOMIZED PHASE-III STUDY OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA CLINICAL-TRIALS GROUP
    SWENERTON, K
    JEFFREY, J
    STUART, G
    ROY, M
    KREPART, G
    CARMICHAEL, J
    DROUIN, P
    STANIMIR, R
    OCONNELL, G
    MACLEAN, G
    KIRK, ME
    CANETTA, R
    KOSKI, B
    SHELLEY, W
    ZEE, B
    PATER, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) : 718 - 726
  • [39] CIS-PLATINUM IN THE TREATMENT OF ADVANCED OR RECURRENT ADENOCARCINOMA OF THE OVARY - A PHASE-II STUDY OF THE GYNECOLOGIC-ONCOLOGY-GROUP
    THIGPEN, JT
    LAGASSE, L
    HOMESLEY, H
    BLESSING, JA
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1983, 6 (04): : 431 - 435
  • [40] CISPLATIN (P) VERSUS CYCLOPHOSPHAMIDE, ADRIAMYCIN AND CISPLATIN (CAP) FOR STAGE-III-IV EPITHELIAL OVARIAN-CARCINOMA - A PROSPECTIVE RANDOMIZED TRIAL
    TOMIROTTI, M
    PERRONE, S
    GIE, P
    CANALETTI, R
    CARPI, A
    BIASOLI, R
    LOMBARDI, F
    GIOVANNINETTI, A
    MENSI, F
    VILLA, S
    SCANNI, A
    [J]. TUMORI, 1988, 74 (05) : 573 - 577